RXRX
NEUTRAL
$3.78
Live
Recursion Pharmaceuticals, Inc. · NASDAQ
Target $6.71
(+77.6%)
$2.8
52W Range
$7.18
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 19, 2026
Market cap
$2.0B
P/E
N/A
ROE
-59.5%
Profit margin
N/A
Debt/Equity
0.07
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
75%
RXRX presents a classic high-risk, high-reward biotech profile, characterized by a stable Piotroski F-Score of 4/9 and a strong liquidity position (Current Ratio 5.50). While revenue growth is astronomical at 681.70% YoY, the company suffers from extreme operating losses (-328.80% margin) and a bearish insider sentiment. The lack of an Altman Z-Score and Graham Number reflects the pre-profit nature of the business, making it a speculative play on AI-driven drug discovery rather than a value investment.
Key Strengths
Exceptional YoY revenue growth of 681.70%
Very low leverage with a Debt/Equity ratio of 0.07
Strong short-term liquidity (Current Ratio 5.50, Quick Ratio 5.20)
Significant analyst upside potential with a target price of $6.71
Recent short-term price momentum (+15.2% over 1 week)
Key Risks
Severe operating losses with an operating margin of -328.80%
Extremely high valuation relative to sales (P/S ratio of 26.74)
Consistent insider selling, including transactions by the CEO and CFO
Long-term price erosion with a 5-year change of -86.5%
High dependency on future clinical success and AI platform validation
AI Fair Value Estimate
Based on comprehensive analysis
$5.25
+38.9% above current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
39
Weak
20
85
30
60
0
AI Verdict
Speculative Growth
Key drivers: Hyper-growth revenue, Clean balance sheet, Deep operational losses, Bearish insider activity
Confidence
80%
Value
20/100
Trades at a significant premium due to AI-biotech growth expectations.
Positives
- Price/Book is relatively modest at 1.77
Watchpoints
- P/S ratio of 26.74 is prohibitively high
- No positive earnings for P/E or Graham Number calculation
Future
85/100
Growth metrics are elite, though not yet translating to profitability.
Positives
- 681.70% YoY revenue growth
- 683.66% Q/Q revenue growth
- Positive EPS growth trend (+60.4% YoY)
Watchpoints
- High burn rate must be sustained by capital raises or partnerships
Past
30/100
Long-term historical performance is poor, indicating a struggle to maintain valuation.
Positives
- Recent 1-month recovery of 13.9%
Watchpoints
- 5-year return of -86.5%
- 1-year return of -31.3%
Health
60/100
Financial health is supported by a strong cash runway rather than operational efficiency.
Positives
- Piotroski F-Score of 4/9 (Stable)
- Very low Debt/Equity (0.07)
- High Current Ratio (5.50)
Watchpoints
- Negative ROE (-59.54%) and ROA (-27.72%)
Dividend
0/100
Typical for early-stage biotech focusing on R&D.
Positives
No standout positives identified.
Watchpoints
- No dividend paid
- 0/100 dividend strength
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$3.78
Analyst Target
$6.71
Upside/Downside
+77.6%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for RXRX and closest competitors.
Updated 2026-04-17
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
RXRX
Recursion Pharmaceuticals, Inc.
Primary
|
-86.5% | -36.4% | -31.3% | -35.5% | +13.9% | +15.2% |
|
ADPT
Adaptive Biotechnologies Corporation
Peer
|
-69.3% | +61.8% | +83.7% | +4.4% | -15.7% | -11.4% |
|
AORT
Artivion, Inc.
Peer
|
+72.4% | +236.1% | +40.5% | +37.0% | -8.2% | -0.8% |
|
ATRC
AtriCure, Inc.
Peer
|
-33.0% | -7.6% | -3.2% | +24.0% | -3.6% | +0.0% |
|
OCUL
Ocular Therapeutix, Inc.
Peer
|
-43.9% | +53.6% | +18.3% | -25.4% | +3.2% | +5.8% |
RXR
Recursion Pharmaceuticals, Inc.
Primary
5Y
-86.5%
3Y
-36.4%
1Y
-31.3%
6M
-35.5%
1M
+13.9%
1W
+15.2%
ADP
Adaptive Biotechnologies Corporation
Peer
5Y
-69.3%
3Y
+61.8%
1Y
+83.7%
6M
+4.4%
1M
-15.7%
1W
-11.4%
AOR
Artivion, Inc.
Peer
5Y
+72.4%
3Y
+236.1%
1Y
+40.5%
6M
+37.0%
1M
-8.2%
1W
-0.8%
ATR
AtriCure, Inc.
Peer
5Y
-33.0%
3Y
-7.6%
1Y
-3.2%
6M
+24.0%
1M
-3.6%
1W
+0.0%
OCU
Ocular Therapeutix, Inc.
Peer
5Y
-43.9%
3Y
+53.6%
1Y
+18.3%
6M
-25.4%
1M
+3.2%
1W
+5.8%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-4.44
PEG Ratio
N/A
P/B Ratio
1.77
P/S Ratio
26.74
EV/Revenue
17.79
EV/EBITDA
-2.35
Market Cap
$2.0B
Profitability
Profit margins and return metrics
Profit Margin
N/A
Operating Margin
-328.8%
Gross Margin
N/A
ROE
-59.54%
ROA
-27.72%
Growth
Revenue and earnings growth rates
Revenue Growth
+681.7%
Earnings Growth
N/A
Q/Q Revenue Growth
+683.66%
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.07
Low debt
Current Ratio
5.5
Strong
Quick Ratio
5.2
Excellent
Cash/Share
$1.41
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.0B
Gross Margin
59.6%
Op. Margin
-306.5%
Net Margin
-305.9%
Total Assets
$1.5B
Liabilities
$0.3B
Equity
$1.1B
Debt/Equity
0.30x
Operating CF
$-0.0B
CapEx
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
103%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-05
$N/A
2026-02-25
$-0.21
+33.3% surprise
2025-11-05
$-0.36
+5.7% surprise
2025-08-05
$-0.41
-16.0% surprise
Healthcare Sector Comparison
Comparing RXRX against 447 companies in the Healthcare sector
(26 bullish, 140 neutral, 281 bearish)
Return on Equity (ROE)
-59.54%
This Stock
vs
-97.42%
Sector Avg
-38.9%
(Below Avg)
Debt to Equity
0.07
This Stock
vs
3.06
Sector Avg
-97.7%
(Less Debt)
Revenue Growth
681.7%
This Stock
vs
147.85%
Sector Avg
+361.1%
(Fast Growth)
Current Ratio
5.5
This Stock
vs
4.68
Sector Avg
+17.7%
(Stronger)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
RXRX
Recursion Pharmaceuticals, Inc.
|
NEUTRAL | $2.0B | - | -59.5% | -% | $3.78 | |
|
ADPT
Adaptive Biotechnologies...
|
BEARISH | $2.03B | - | -27.8% | -21.5% | $13.17 | Compare |
|
AORT
Artivion, Inc.
|
BEARISH | $2.04B | - | -2.5% | -2.2% | $43.02 | Compare |
|
ATRC
AtriCure, Inc.
|
NEUTRAL | $1.94B | - | -6.1% | -5.6% | $39.07 | Compare |
|
OCUL
Ocular Therapeutix, Inc.
|
NEUTRAL | $1.94B | - | -54.9% | -% | $8.91 | Compare |
RXRX
Recursion...
NEUTRAL
Mkt Cap
$2.0B
P/E
-
ROE
-59.5%
Price
$3.78
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-07 | GIBSON CHRISTOPHER | Director | Sale | 40,000 | $124,000 |
| 2026-04-07 | GIBSON CHRISTOPHER | Director | Stock Award | 40,000 | - |
| 2026-04-07 | BORGESON BLAKE CHARLES | Director | Sale | 30,000 | $93,000 |
| 2026-04-01 | DAR ZAVAIN | Director | Stock Award | 4,902 | - |
| 2026-04-01 | LI DEAN Y | Director | Stock Award | 3,268 | - |
| 2026-03-23 | GIBSON CHRISTOPHER | Director | Sale | 40,000 | $130,000 |
| 2026-03-23 | GIBSON CHRISTOPHER | Director | Stock Award | 40,000 | - |
| 2026-03-17 | TAYLOR BEN R | Chief Financial Officer | Sale | 7,956 | $26,971 |
| 2026-03-09 | GIBSON CHRISTOPHER | Director | Gift | 20,000 | - |
| 2026-03-09 | GIBSON CHRISTOPHER | Director | Stock Award | 20,000 | - |
| 2026-03-09 | KHAN NAJAT | Chief Executive Officer | Sale | 28,298 | $94,660 |
| 2026-03-03 | BORGESON BLAKE CHARLES | Director | Sale | 170,000 | $588,200 |
| 2026-02-19 | GIBSON CHRISTOPHER | Director | Sale | 40,000 | $138,400 |
| 2026-02-19 | GIBSON CHRISTOPHER | Director | Stock Award | 40,000 | - |
| 2026-02-18 | TAYLOR BEN R | Chief Financial Officer | Sale | 13,426 | $41,352 |
GIBSON CHRISTOPHER
Director
2026-04-07
40,000 shares
·
$124,000
GIBSON CHRISTOPHER
Director
2026-04-07
40,000 shares
BORGESON BLAKE CHARLES
Director
2026-04-07
30,000 shares
·
$93,000
DAR ZAVAIN
Director
2026-04-01
4,902 shares
LI DEAN Y
Director
2026-04-01
3,268 shares
GIBSON CHRISTOPHER
Director
2026-03-23
40,000 shares
·
$130,000
GIBSON CHRISTOPHER
Director
2026-03-23
40,000 shares
TAYLOR BEN R
Chief Financial Officer
2026-03-17
7,956 shares
·
$26,971
GIBSON CHRISTOPHER
Director
2026-03-09
20,000 shares
GIBSON CHRISTOPHER
Director
2026-03-09
20,000 shares
KHAN NAJAT
Chief Executive Officer
2026-03-09
28,298 shares
·
$94,660
BORGESON BLAKE CHARLES
Director
2026-03-03
170,000 shares
·
$588,200
GIBSON CHRISTOPHER
Director
2026-02-19
40,000 shares
·
$138,400
GIBSON CHRISTOPHER
Director
2026-02-19
40,000 shares
TAYLOR BEN R
Chief Financial Officer
2026-02-18
13,426 shares
·
$41,352
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
BUY
7 analysts
B of A Securities
2026-02-26
Neutral
Neutral
Needham
2026-02-26
Buy
Buy
JP Morgan
2025-12-17
Neutral
Overweight
Past News Coverage
Recent headlines mentioning RXRX from our newsroom.
Newest → oldest
No matching news yet.